Released May 5, 2026, after the close
10-Q filed May 6, 2026, 36 days after period end · 0001193125-26-208967
Q1 2026 · 10-Q
Revenue$21.15M$21.15M +4.6% vs Q1 2025−11.1% vs Q4 2025
Net Income$127.07M$127.07M N/M vs Q1 2025+559.0% vs Q4 2025
EPS Diluted$0.33$0.33 N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$11,308,000+2.3%
Operating Income-$12,496,000N/M
Operating Cash Flow-$46,597,000N/M
Free Cash Flowderived-$47,167,000N/M
Margins · derived
Gross margin53.5%−1.2 pt vs Q1 2025
Operating margin-59.1%+74.3 pt vs Q1 2025
Net margin600.9%+729.6 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $21.15M | $20.22M | $45.54M | $25.12M |
| Net Income | $127.07M | -$26.03M | -$32.16M | -$16.84M |
| EPS Diluted | $0.33 | -$0.07 | -$0.27 | -$0.21 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR